Linezolid

Generic Name: Linezolid

Brand Names: Zyvox, Zyvoxam

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₀FN_₃O_₄

CAS Number: 165800-03-3

Unique Ingredient Identifier: ISQ9I6J12J

Background: Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...

Indication: Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...

Associated Conditions: Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection

Associated Therapies: -

Clinical Trials

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Phase 3

Completed

Conditions: Community Acquired Pneumonia

Interventions: Drug: lefamulin
Drug: Moxifloxacin
Drug: Linezolid

First Posted Date: 2015-09-24

Last Posted Date: 2019-10-23

Lead Sponsor: Nabriva Therapeutics AG

Target Recruit Count: 551

Registration Number: NCT02559310

Locations: 🇦🇷
Site 3005, La Plata, Buenos Aires, Argentina
🇦🇷
Site 3007, Córdoba, Argentina
🇦🇷
Site 3001, Córdoba, Argentina

and more 96 locations

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Phase 3

Completed

Conditions: Bacterial Pneumonia

Interventions: Drug: Imipenem
Drug: Piperacillin
Drug: Relebactam
Drug: Tazobactam
Drug: Cilastatin
Drug: Linezolid

First Posted Date: 2015-07-09

Last Posted Date: 2020-04-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 537

Registration Number: NCT02493764

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis
Multidrug Resistant Tuberculosis
Extensively-drug Resistant Tuberculosis

Interventions: Drug: Pyrazinamide
Drug: Linezolid
Drug: Ethionamide
Drug: Bedaquiline
Drug: Terizidone
Drug: Levofloxacin
Drug: Moxifloxacin
Drug: Kanamycin
Drug: Isoniazid

First Posted Date: 2015-05-27

Last Posted Date: 2021-09-29

Lead Sponsor: University of Cape Town

Target Recruit Count: 154

Registration Number: NCT02454205

Locations: 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa

Study of Debio 1450 for Bacterial Skin Infections

Phase 2

Completed

Conditions: Bacterial Infections

Interventions: Drug: Debio 1450 IV
Drug: Linezolid
Drug: Debio 1450 Oral Placebo
Drug: Debio 1450 Oral
Drug: Linezolid Placebo
Drug: Vancomycin IV

First Posted Date: 2015-04-27

Last Posted Date: 2019-11-13

Lead Sponsor: Debiopharm International SA

Target Recruit Count: 330

Registration Number: NCT02426918

Locations: 🇺🇸
Beaumont Infectious Disease Services, Royal Oak, Michigan, United States
🇺🇸
Dream Team Clinical Research, LLC, Anaheim, California, United States
🇺🇸
eStudySite - Chula Vista, Chula Vista, California, United States

and more 19 locations

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Phase 3

Completed

Conditions: Skin Structures and Soft Tissue Infections
Bacterial Infections

Interventions: Drug: Omadacycline
Drug: Linezolid

First Posted Date: 2015-03-04

Last Posted Date: 2019-03-21

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 655

Registration Number: NCT02378480

Locations: 🇺🇸
Site 256, Augusta, Georgia, United States
🇺🇸
Site 252, Santa Ana, California, United States
🇺🇸
Site 259, Miami, Florida, United States

and more 75 locations

A Phase 3 Study Assessing Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis

Phase 3

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Bedaquiline
Drug: PA-824
Drug: Linezolid

First Posted Date: 2015-01-07

Last Posted Date: 2024-08-09

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 109

Registration Number: NCT02333799

Locations: 🇿🇦
Task Applied Science - Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa
🇿🇦
King DinuZulu Hospital Complex, Sydenham, Durban, South Africa
🇿🇦
Sizwe Tropical Disease Hospital, Sandringham, Johannesburg, South Africa

A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Linezolid
Drug: HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)

First Posted Date: 2014-10-31

Last Posted Date: 2019-01-11

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 113

Registration Number: NCT02279875

Locations: 🇿🇦
TASK Clinical Research Centre, Bellville, Cape Town, South Africa
🇿🇦
University of Cape Town Lung Institute (Pty) Ltd, Mowbray, Cape Town, South Africa